# Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

> **NCT00086944** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 25 (actual)

## Conditions studied

- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma

## Interventions

- **BIOLOGICAL:** oblimersen sodium
- **BIOLOGICAL:** rituximab
- **DRUG:** ifosfamide
- **DRUG:** carboplatin
- **DRUG:** etoposide
- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** pegfilgrastim
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00086944
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2006-07
- **Final completion:** —
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2013-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00086944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00086944, "Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00086944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*